天境生物上涨10.61%，报4.69美元/股，总市值5.39亿美元

Core Viewpoint - Tianjing Bio (IMAB) has shown significant stock performance and financial growth, indicating a strong position in the innovative biopharmaceutical sector focused on oncology and autoimmune diseases [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a 41.54% increase compared to the previous year [1]. Upcoming Events - Tianjing Bio is scheduled to release its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [2]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to create groundbreaking innovative biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2].